Predicting Chemo Toxicity Using Geriatric Forms

NCT07163169 | Active Not Recruiting

• 1 other identifier: COMU-FNO-1
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational study aims to evaluate and compare the effectiveness of three geriatric assessment tools-CARG (Cancer and Aging Research Group score), G8 screening tool, and Frailty Scale-in predicting chemotherapy-related toxicity (CRT) in cancer patients aged 65 years and older. A total of at least 100 patients receiving standard chemotherapy (excluding hematologic malignancies and immunotherapy) at Çanakkale University Medical Faculty Oncology Clinic will be assessed prior to treatment initiation. Each participant will undergo baseline evaluations including G8, CARG, and Frailty assessments. The study will analyze the correlation between these tools and the occurrence of CRT using AUC, logistic regression, and correlation analyses. The goal is to identify the most accurate and practical screening tool to guide clinical decision-making and minimize chemotherapy toxicity in older adults.

Conditions

Oncology; Geriatric Oncology; Physiology

Keywords

geriatric oncology; chemotoxicity

Outcome Measures

Primary Outcomes (3)

• Geriartric Form Results and Chemotherapy Side Effects

  ARG (Cancer and Aging Research Group score)

  From enrollment to 6 month

• G8 screening tool

  prediction side effets on chemotherapy on patient

  From enrollment to 6 month

• Frailty Scale

  Predicting side effect chemoterapy in elderly patient

  From enrollment to 6 month

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population will consist of adult oncology patients aged 65 years and older who are scheduled to receive systemic chemotherapy for solid tumors at the Çanakkale Onsekiz Mart University Medical Faculty, Department of Medical Oncology. Eligible participants must have a confirmed cancer diagnosis and a predefined chemotherapy regimen (adjuvant, neoadjuvant, or palliative), but must not have yet started treatment at the time of enrollment.

You may qualify if:

• Patients aged 65 years or older.
• Histologically confirmed cancer diagnosis with a pre-planned chemotherapy regimen (adjuvant, neoadjuvant, or palliative intent).
• Chemotherapy not yet initiated at the time of enrollment.
• Clinically stable condition, as assessed by the oncologist.
• Willingness and ability to provide written informed consent.

You may not qualify if:

• Presence of acute infection or advanced organ failure (cardiac, hepatic, or renal).
• Severe psychiatric illness or cognitive impairment that interferes with the ability to complete assessments.
• Patients receiving concurrent hormonal therapy, targeted therapy, immunotherapy, or radiotherapy.
• Diagnosis of hematologic malignancies (e.g., leukemia, lymphoma, myeloma).

Sponsors & Collaborators

• Çanakkale Onsekiz Mart University: lead

Study Sites (1)

Çanakkale Onsekiz Mart Univercity

Çanakkale, 17020, Turkey (Türkiye)

Location

Related Publications (12)

• Runzer-Colmenares FM, Urrunaga-Pastor D, Roca-Moscoso MA, De Noriega J, Rosas-Carrasco O, Parodi JF. Frailty and Vulnerability as Predictors of Chemotherapy Toxicity in Older Adults: A Longitudinal Study in Peru. J Nutr Health Aging. 2020;24(9):966-972. doi: 10.1007/s12603-020-1404-6.

  PMID: 33155622 BACKGROUND

• Retornaz F, Guillem O, Rousseau F, Morvan F, Rinaldi Y, Nahon S, Castagna C, Boulahssass R, Grino M, Gholam D. Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study. Oncologist. 2020 Jan;25(1):e85-e93. doi: 10.1634/theoncologist.2019-0241. Epub 2019 Aug 6.

  PMID: 31387952 BACKGROUND

• Ostwal V, Ramaswamy A, Bhargava P, Hatkhambkar T, Swami R, Rastogi S, Mandavkar S, Ghosh J, Bajpai J, Gulia S, Srinivas S, Rath S, Gupta S. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. BMJ Open. 2021 Jun 29;11(6):e047376. doi: 10.1136/bmjopen-2020-047376.

  PMID: 34187825 BACKGROUND

• Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P, Pepersack T, Luce S, Langenaeken C, Rasschaert M, Allepaerts S, Van Rijswijk R, Milisen K, Flamaing J, Lobelle JP, Wildiers H. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol. 2013 May;24(5):1306-12. doi: 10.1093/annonc/mds619. Epub 2013 Jan 4.

  PMID: 23293115 BACKGROUND

• Juthani R, Punatar S, Mittra I. New light on chemotherapy toxicity and its prevention. BJC Rep. 2024 May 22;2(1):41. doi: 10.1038/s44276-024-00064-8.

  PMID: 39516565 BACKGROUND

• Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011 Sep 1;29(25):3457-65. doi: 10.1200/JCO.2011.34.7625. Epub 2011 Aug 1.

  PMID: 21810685 BACKGROUND

• Goede V. Frailty and Cancer: Current Perspectives on Assessment and Monitoring. Clin Interv Aging. 2023 Mar 28;18:505-521. doi: 10.2147/CIA.S365494. eCollection 2023.

  PMID: 37013130 BACKGROUND

• Feliu J, Jimenez-Munarriz B, Basterretxea L, Paredero I, Llabres E, Antonio-Rebollo M, Losada B, Espinosa E, Girones R, Custodio AB, Del Mar Munoz M, Diaz-Almiron M, Gomez-Mediavilla J, Pinto A, Torregrosa MD, Soler G, Cruz P, Higuera O, Molina-Garrido MJ. Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study. Oncologist. 2020 Oct;25(10):e1516-e1524. doi: 10.1634/theoncologist.2019-0701. Epub 2020 Apr 30.

  PMID: 32329131 BACKGROUND

• Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanesvaran R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol. 2015 Feb;26(2):288-300. doi: 10.1093/annonc/mdu210. Epub 2014 Jun 16.

  PMID: 24936581 BACKGROUND

• Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020 Oct 7;20(1):393. doi: 10.1186/s12877-020-01801-7.

  PMID: 33028215 BACKGROUND

• Chon J, Timilshina N, AlMugbel F, Jin R, Monginot S, Tejero I, Breunis H, Alibhai SMH. Validity of a self-administered G8 screening test for older patients with cancer. J Geriatr Oncol. 2023 Sep;14(7):101553. doi: 10.1016/j.jgo.2023.101553. Epub 2023 Jun 26.

  PMID: 37379768 BACKGROUND

• Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 Aug;23(8):2166-2172. doi: 10.1093/annonc/mdr587. Epub 2012 Jan 16.

  PMID: 22250183 BACKGROUND

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Reseach Asistant, Dr.

Study Record Dates

• First Submitted: July 30, 2025
• First Posted: September 9, 2025
• Study Start: December 10, 2024
• Primary Completion: December 20, 2025
• Study Completion (Estimated): December 20, 2026
• Last Updated: September 9, 2025

Record last verified: 2024-12

Locations

TU (1)